Adverse effects of prostaglandin analogues used in ophthalmological practice
https://doi.org/10.21516/2072-0076-2021-14-2-85-89
Abstract
Prostaglandin analogues are a class of antihypertensive drugs for glaucoma treatment which are systematically safe but have a sufficiently large number of local side effects. These effects may worsen the quality of life of patients with glaucoma and reducetheir adherence to treatment routines due to physical and psychological discomfort. The review presents literature data and clinical cases fromthe author’s own medical practice.
About the Author
S. Yu. Kazanova
Central City Hospital
Russian Federation
Russian Federation
Svetlana Yu. Kazanova — Cand. of Med. Sci., head of the ophthalmological department of consultative and diagnostic No.1 (glaucoma department)
52, Ave. Oktyabrya, Yaroslavl, 150040
References
1. European Glaucoma Society. Terminology and guidelines for glaucoma. 4th ed. Savona: Italy PubliComm; 2014.
2. Egorov E.A., Erichev V.P.Medicamental antihypertensive treatment of glaucoma. In: Egorov E.A., ed. Glauсoma. Nacional Guidelines. Moscow: GEOTAR-Media; 2013: 427–67 (in Russian)].
3. Weinreb R.N., Kashiwagi K., Kashiwagi F., Tsukahara S., Lindsey J.D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 1997; 38 (13): 2772–80.
4. Sharif N.A., Kelly C.R., Crider J.Y. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and ot her prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J. Ocul. Pharmacol. Ther. 2002; 18 (4): 313–24. doi: 10.1089/10807680260218489
5. Sharif N.A., Kelly C.R., Crider J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Sci. 2003; 44 (2): 715–21. doi: 10.1167/iovs.02-0323
6. Ota T., Aihara M., Narumiya S., Araie M.The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 2005; 46 (11): 4159–63. doi: 10.1167/iovs.05-0494
7. Toris C.B., Gabelt B.T., Kaufman P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol. 2008; 53 (Suppl 1): S107–20. doi: 10.1016/j.survophthal.2008.08.010
8. Lim K.S., Nau C.B., O'Byrne M.M., et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008; 115 (5): 790-5.e4. doi: 10.1016/j.ophtha.2007.07.002
9. Neacsu A.M. Receptors involved in the mechanism of action of topical prostaglandins. [Article in Romanian]. Oftalmologia. 2009; 53 (2): 3–7.
10. Shah M., Lee G., Lefebvre D.R., et al.A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features. PLoS One. 2013 ; 8 (5):e61638. doi: 10.1371/journal.pone.0061638
11. Alm A., Grierson I., Shields M.B. Side effects associated with prostaglandin analog therapy. Surv. Ophthalmol. 2008; 53 (Suppl 1): S93–105. doi: 10.1016/j.survophthal.2008.08.004
12. Varfolomeev S.D.Prostaglandins - a new type of biological regulators. Sorosovskij obrazovatel'nyj zhurnal. 1996; 1: 40–7 (in Russian)].
13. Egorova T.E. Prostaglandins in glaucoma treatment. RMZh. Klinicheskaja oftal'mologija. 2004; 5 (3): 127–31 (in Russian).
14. Erichev V.P., Zinina V.S. Latanoprost in hypotensive therapy of glaucoma. Vestnik oftal'mologii. 2018; 4: 91–9 (in Russian). doi: 10.17116/oftalma201813404191]
15. European Glaucoma Society. Terminology and guidelines for glaucoma. 2th ed. Savona: Italy DOGMA; 2003.
16. Honrubia F., Garc a-S nchez J., Polo V., de la Casa J.M., Soto J. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br. J. Ophthalmol. 2009; 93 (3): 316–21. doi: 10.1136/bjo.2007.135111
17. Hommer A., Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clinical Ophthalmology. 2011; 5: 623–31. doi: 10.2147/opth.s17876
18. Law S.K.Bimatoprost in the treatment of eyelash hypotrichosis. Clin. Ophthalmol. 2010; 26 (4): 349–58. doi: 10.2147/opth.s6480
19. Johnstone M.A., Albert D.M.Prostaglandin-induced hair growth. Surv. Ophthalmol. 2002; 47 (Suppl 1): S185–202. doi: 10.1016/s0039-6257(02)00307-7
20. Blume-Peytavi U., Lönnfors S., Hillmann K., Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1 % on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J. Am. Acad. Dermatol. 2012; 66 (5): 794–800. doi: 10.1016/j.jaad.2011.05.026
21. Jones D. Enhanced eyelashes: prescription and over-the-counter options. Aesthetic Plast. Surg. 2011; 35 (1): 116–21. doi: 10.1007/s00266-010-9561-3
22. Barrón-Hernández Y.L., Tosti A.Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert. Opin. Investig. Drugs. 2017; 26 (4): 515–22. doi: 10.1080/13543784.2017.1303480
23. Grierson I., Jonsson M., Cracknell K. Latanoprost and pigmentation. Jpn. J. Ophthalmol. 2004; 48 (6): 602–12. doi: 10.1007/s10384-004-0110-y
24. Alekseev I.B., Strakhov V.V., Mel'nikova N.V., Popova A.A. Changes in the fibrous tunic of the eye in patients with newly diagnosed primary open-angle glaucoma. Nacional'nyj zhurnal glaukoma. 2016; 15 (1): 13–24 (in Russian)].
25. Nordmann J.P., Auzanneau N., Ricard S., Berdeaux G. Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes. 2003; 10 (1):75. doi: 10.1186/1477-7525-1-75
26. Belogurova A.V., Eskina E.N., Oganezova Zh.G.IOP-lowering effect and tolerability of prostaglandin analogues in primary open angleglaucoma and ocular hypertension as risk factors for glaucoma progression. RMZh. Klinicheskaja oftal'mologija. 2019; 19 (1): 21–6 (in Russian). doi: 10.21689/2311-7729-2019-19-1-21-26]
27. Astakhov Yu.S., Nechiporenko P.A.Prostaglandin analogues: past, present, and future. Oftal'mologicheskie vedomosti. 2017; 10 (1): 40–52 (in Russian). doi: 10.17816/OV10140-52]
28. Chiba T., Kashiwagi K., Kogure S., et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J. Glaucoma. 2001; 10 (5): 406–10. doi: 10.1097/00061198-200110000-00008
29. Azamatova G.A., Arslanova A.I., Aboimova E.V. Iris hyperpigmentation during treatment with prostaglandin analogues. Medicinskij vestnik Bashkortostana. 2016; 11 (1): 143–5 (in Russian)].
30. Camras C.B., Neely D.G., Weiss E.L., et al. Latanoprost-induced iris color darkening: a case report with long-term follow-up. J. Glaucoma. 2000; 9 (1): 95–8. doi: 10.1097/00061198-200002000-00016
31. Erichev V.P., Jakubova L.V. Clinical safety assessment of the long-term use of xalatan (literature review). Glaukoma. 2004; 1: 74–81 (in Russian).
32. Wistrand P.J., Stjernschantz J., Olsson K. at al. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Opthtalmol. 1997; 41 (Suppl. 2): S129–38. doi: 10.1016/s0039-6257(97)80020-3
33. Tsai J.C., Sivak-Callcott J.A., Haik B.G., et al. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J. Glaucoma. 2001; 10 (5): 411–3. doi: 10.1097/00061198-200110000-00009
34. Zhan G., Toris C., Camras C., et al. Prostaglandin-induced iris color darkening: an experimental model. Arch. Opthtalmol. 1998; 116 (8): 1065–8. doi:10.1001/archopht.116.8.1065
35. Mancino R., Di Carlo E., Napoli D., еt al.Anterior segment Optical Coherence Tomography Analysis of iris morphometric changes induced by prostaglandin analogues treatment in patients with primary open angle glaucoma or ocular hypertension. Open Ophthalmol. J. 2018; 29 (12): 110–20. doi: 10.2174/1874364101812010110
36. Korotkih S.A., Zhiborkin G.V., Knjazeva E.S., Rusakova L.V. The efficiency of monotherapy of patients with primary open-angle glaucoma with Bimatoprost 0.03 % (Bimoptic). Russian ophthalmological journal. 2018; 11 (4): 75–9 (in Russian). doi: 10.21516/2072-0076-2018-11-4-75-79]
37. Yam J.C., Yuen N.S., Chan C.W.Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J. Ocul. Pharmacol. Ther. 2009; 25 (5): 471–2. doi: 10.1089/jop.2009.0019
38. Peplinski L.S., Albiani Smith K.Deepening of lid sulcus from topical bimatoprost therapy. Optom. Vis. Sci. 2004; 81 (8): 574–7. doi: 10.1097/01.opx.0000141791.16683.4a
39. Накакура S., Tabuchi Н., Kiuchi Y. Latanoprost therapy after sunken eyes caused by travoprost or bimatoprost. Optom. Vis. Sci. 2011; 88 (9): 1140–4. doi: 10.1097/OPX.0b013e3182231202
40. Tappeiner C., Perren B., Iliev M.E., Frueh B.E., Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost - can bimatoprost cause enophthalmos? [in German]. Klin. Monbl. Augenheilkd. 2008; 225 (5): 443–5. doi: 10.1055/s-2008-1027362
41. Filippopoulos T., Paula J.S., Torun N., et al. Periorbital changes associated with topical bimatoprost. Ophthalmic. Plast. Reconstr. Surg. 2008; 24 (4): 302–7. doi: 10.1097/IOP.0b013e31817d81df
42. Jayaprakasam A., Ghazi-Nouri S. Periorbital fat atrophy – an unfamiliar side effect of prostaglandin analogues. Orbit. 2010; 29 (6): 357–9. doi: 10.3109/01676830.2010.527028
43. Aihara M., Shirato S., Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn. J. Ophthalmol. 2011; 55 (6): 600–4. doi: 10.1007/s10384-011-0075-6
44. Rabinowitz M.P., Katz L.J., Moster M.R., et al. Unilateral prostaglandinassociated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthal. Plast. Reconstr. Surg. 2015; 31 (5): 373–8. doi: 10.1097/IOP.0000000000000351
45. Kim H.W., Choi Y.J., Lee K.W., Lee M.J. Periorbital changes associated with prostaglandin analogs in Korean patients. BMC Ophthalmol. 2017; 17 (1): 126. doi: 10.1186/s12886-017-0521-4
46. Kucukevcilioglu M., Bayer A., Uysal Y., Altinsoy H.I. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin. Exp. Ophthalmol. 2014; 42 (2): 126–31. doi: 10.1111/ceo.12163
47. Inoue K., Shiokawa M., Wakakura M., Tomita G.Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J. Glaucoma. 2013; 22 (8): 626–31. doi: 10.1097/IJG.0b013e31824d8d7c
48. Park J., Cho H.K., Moon J.I.Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn. J. Ophthalmol. 2011; 55 (1): 22–7. doi: 10.1007/s10384-010-0904-z
49. Ung T., Currie Z.I. Periocular changes following long-term administration of latanoprost 0.005%. Ophthalmic. Plast. Reconstr. Surg. 2012; 28 (2): e42-4. doi: 10.1097/IOP.0b013e31821d86a5
50. Kim J.W.Topical prostaglandin analogue drugs inhibit adipocyte differentiation. Korean J. Ophthalmol. 2014; 28 (3): 257–64. doi: 10.3341/kjo.2014.28.3.257
51. Higashiyama T., Ohji M.Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy. Clin. Ophthalmol. 2018; 12: 2415–21. doi: 10.2147/OPTH.S187164
52. Aydin S., Işikligil I., Tekşen Y.A., Kir E. Recovery of orbital fat pad prolapsus and deepening of the lid sulcus from topical bimatoprost therapy: 2 case reports and review of the literature. Cutan. Ocul. Toxicol. 2010; 29 (3): 212–6. doi: 10.3109/15569521003796860
Review
For citations:
Kazanova S.Yu. Adverse effects of prostaglandin analogues used in ophthalmological practice. Russian Ophthalmological Journal. 2021;14(2):85-89. (In Russ.) https://doi.org/10.21516/2072-0076-2021-14-2-85-89
Views:
2825
Email this article 